ConductScience.org, home

Trial · NCT02554903

Results by group22

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Pulmonary Vascular Resistance (PVR) Ratio of Week 12 to BaselineMacitentan 10 Milligrams (mg)0.585Standard Deviation 0.2280Ratio
Pulmonary Vascular Resistance (PVR) Ratio of Week 12 to BaselinePlacebo0.757Standard Deviation 0.2578Ratio
Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP)Macitentan 10 Milligrams (mg)0.8Standard Deviation 5.49millimeters of mercury (mmHg)
Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP)Placebo-1.4Standard Deviation 4.71millimeters of mercury (mmHg)
Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP)Macitentan 10 Milligrams (mg)-3.84Standard Deviation 8.821mmHg
Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP)Placebo-3.86Standard Deviation 7.982mmHg
Change From Baseline to Week 12 in Pulmonary Arterial Wedge Pressure (PAWP)Macitentan 10 Milligrams (mg)4.0Standard Deviation 7.86mmHg
Change From Baseline to Week 12 in Pulmonary Arterial Wedge Pressure (PAWP)Placebo1.0Standard Deviation 4.93mmHg
Change From Baseline to Week 12 in Cardiac Index (CI)Macitentan 10 Milligrams (mg)0.093Standard Deviation 0.4680L/min/m^2
Change From Baseline to Week 12 in Cardiac Index (CI)Placebo0.041Standard Deviation 0.4576L/min/m^2
Change From Baseline to Week 12 in Total Pulmonary Resistance (TPR)Macitentan 10 Milligrams (mg)-1.399Standard Deviation 2.2515Wood Unit
Change From Baseline to Week 12 in Total Pulmonary Resistance (TPR)Placebo-0.993Standard Deviation 2.2596Wood Unit
Change From Baseline to Week 12 in Mixed Venous Oxygen Saturation (SvO2)Macitentan 10 Milligrams (mg)4.260Standard Deviation 17.1523Percentage of SvO2
Change From Baseline to Week 12 in Mixed Venous Oxygen Saturation (SvO2)Placebo4.100Standard Deviation 8.5202Percentage of SvO2
Change From Baseline to Week 12 in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) LevelsMacitentan 10 Milligrams (mg)1325.68Standard Deviation 1214.719nanograms/Liter (ng/L)
Change From Baseline to Week 12 in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) LevelsPlacebo1573.44Standard Deviation 2327.632nanograms/Liter (ng/L)
Change From Baseline to Week 12 in Participants World Health Organization (WHO) Functional Class (FC)Macitentan 10 Milligrams (mg)Worsening2Participants
Change From Baseline to Week 12 in Participants World Health Organization (WHO) Functional Class (FC)PlaceboWorsening2Participants
Change From Baseline to Week 12 in Participants World Health Organization (WHO) Functional Class (FC)Macitentan 10 Milligrams (mg)No change13Participants
Change From Baseline to Week 12 in Participants World Health Organization (WHO) Functional Class (FC)PlaceboNo change15Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02554903/results